Clement C Zai1,2,3,4, Arun K Tiwari1,2, Gwyneth C Zai1,2, Vincenzo de Luca1,2,3, Sajid A Shaikh1, Nicole King1, John Strauss1,2,3,5, James L Kennedy1,2,3, John B Vincent2,3,6. 1. Neurogenetics Section, Molecular Brain Science, Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada. 2. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. 3. Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada. 4. Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. 5. Medical Informatics, Child, Youth, and Family Program, CAMH, Toronto, Ontario, Canada. 6. Molecular Neuropsychiatry and Development (MiND) Laboratory, Campbell Family Mental Health Research Institute, CAMH, Toronto, Ontario, Canada.
Abstract
BACKGROUND: A number of genes have been implicated in recent genome-wide association studies of suicide attempt in bipolar disorder. More focused investigation of genes coding for protein targets of existing drugs may lead to drug repurposing for the treatment and/or prevention of suicide. METHODS: We analyzed 2,457 DNA variants across 197 genes of interest to GlaxoSmithKline across the pipeline in our sample of European patients suffering from bipolar disorder (N = 219). We analyzed these variants for a possible association with the suicide severity score (ranging from suicidal ideation/plan to serious suicide attempt) from the Schedule for Clinical Assessment in Neuropsychiatry. We conducted tests of individual variants and gene-based tests. RESULTS: We found a number of DNA variants in the transforming growth factor beta receptor 1 gene (TGFBR1) to be suggestively associated with suicide severity scores (p < 0.005). The gene-based tests also pointed to TGFBR1 to be associated with suicide severity (p = 0.0001). However, these findings were not replicated in an independent bipolar disorder sample. CONCLUSIONS: We report no significant association between DNA sequences of drug target genes and suicidal behavior. Additional larger sequencing studies could further interrogate associations between variants in drug target genes and suicidal behavior.
BACKGROUND: A number of genes have been implicated in recent genome-wide association studies of suicide attempt in bipolar disorder. More focused investigation of genes coding for protein targets of existing drugs may lead to drug repurposing for the treatment and/or prevention of suicide. METHODS: We analyzed 2,457 DNA variants across 197 genes of interest to GlaxoSmithKline across the pipeline in our sample of European patients suffering from bipolar disorder (N = 219). We analyzed these variants for a possible association with the suicide severity score (ranging from suicidal ideation/plan to serious suicide attempt) from the Schedule for Clinical Assessment in Neuropsychiatry. We conducted tests of individual variants and gene-based tests. RESULTS: We found a number of DNA variants in the transforming growth factor beta receptor 1 gene (TGFBR1) to be suggestively associated with suicide severity scores (p < 0.005). The gene-based tests also pointed to TGFBR1 to be associated with suicide severity (p = 0.0001). However, these findings were not replicated in an independent bipolar disorder sample. CONCLUSIONS: We report no significant association between DNA sequences of drug target genes and suicidal behavior. Additional larger sequencing studies could further interrogate associations between variants in drug target genes and suicidal behavior.
Entities:
Keywords:
Bipolar disorder; Drug target genes; Genetics; Sequencing; Suicide attempt
Authors: Roy H Perlis; Jie Huang; Shaun Purcell; Maurizio Fava; A John Rush; Patrick F Sullivan; Steven P Hamilton; Francis J McMahon; Thomas G Schulze; Thomas Schulze; James B Potash; Peter P Zandi; Virginia L Willour; Brenda W Penninx; Dorret I Boomsma; Nicole Vogelzangs; Christel M Middeldorp; Marcella Rietschel; Markus Nöthen; Sven Cichon; Hugh Gurling; Nick Bass; Andrew McQuillin; Marian Hamshere; Nick Craddock; Pamela Sklar; Jordan W Smoller Journal: Am J Psychiatry Date: 2010-11-01 Impact factor: 18.112
Authors: Murray B Stein; Erin B Ware; Colter Mitchell; Chia-Yen Chen; Susan Borja; Tianxi Cai; Catherine L Dempsey; Carol S Fullerton; Joel Gelernter; Steven G Heeringa; Sonia Jain; Ronald C Kessler; James A Naifeh; Matthew K Nock; Stephan Ripke; Xiaoying Sun; Jean C Beckham; Nathan A Kimbrel; Robert J Ursano; Jordan W Smoller Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2017-09-13 Impact factor: 3.568
Authors: David A Brent; Maria Oquendo; Boris Birmaher; Laurence Greenhill; David Kolko; Barbara Stanley; Jamie Zelazny; Beth Brodsky; Jeffrey Bridge; Steve Ellis; J Octavio Salazar; J John Mann Journal: Arch Gen Psychiatry Date: 2002-09
Authors: Gareth J Inman; Francisco J Nicolás; James F Callahan; John D Harling; Laramie M Gaster; Alastair D Reith; Nicholas J Laping; Caroline S Hill Journal: Mol Pharmacol Date: 2002-07 Impact factor: 4.436
Authors: Alexandra Schosser; Amy W Butler; Marcus Ising; Nader Perroud; Rudolf Uher; Mandy Y Ng; Sarah Cohen-Woods; Nick Craddock; Michael J Owen; Ania Korszun; Lisa Jones; Ian Jones; Michael Gill; John P Rice; Wolfgang Maier; Ole Mors; Marcella Rietschel; Susanne Lucae; Elisabeth B Binder; Martin Preisig; Julia Perry; Federica Tozzi; Pierandrea Muglia; Katherine J Aitchison; Gerome Breen; Ian W Craig; Anne E Farmer; Bertram Müller-Myhsok; Peter McGuffin; Cathryn M Lewis Journal: PLoS One Date: 2011-07-05 Impact factor: 3.240